Technical Analysis for ARGNF - argenx SE

Grade Last Price % Change Price Change
grade A 74.289 -2.30% -1.7466
ARGNF closed down 2.3 percent on Wednesday, October 3, 2018, on 9 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Up
See historical ARGNF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Gapped Down Weakness 0.00%
Narrow Range Bar Range Contraction -2.30%
Outside Day Range Expansion -2.30%
Narrow Range Bar Range Contraction -1.52%
Gapped Down Weakness -1.52%

Older signals for ARGNF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Medicine RTT Medical Specialties Cancer Biopharmaceutical Organ Systems Immunology Immunotherapy Autoimmune Diseases Solid Tumors Monoclonal Antibodies Rheumatoid Arthritis Autoimmunity Leukemia Acute Myeloid Leukemia Treatment Of Autoimmune Diseases Myelodysplastic Syndrome Dyslipidemia Immune Thrombocytopenia Immunosuppressants Myasthenia Gravis
Is ARGNF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 85.0
52 Week Low 14.2584
Average Volume 36,946
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 51.6263
Average True Range 5.2651
ADX 0.0
+DI 84.1291
-DI 13.538
Chandelier Exit (Long, 3 ATRs ) 69.2047
Chandelier Exit (Short, 3 ATRs ) 30.0537
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 13.5916
MACD Signal Line 6.833
MACD Histogram 6.7586
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 74.2890
Resistance 3 (R3) 74.2890 74.2890 74.2890
Resistance 2 (R2) 74.2890 74.2890 74.2890 74.2890
Resistance 1 (R1) 74.2890 74.2890 74.2890 74.2890 74.2890
Pivot Point 74.2890 74.2890 74.2890 74.2890 74.2890
Support 1 (S1) 74.2890 74.2890 74.2890 74.2890 74.2890
Support 2 (S2) 74.2890 74.2890 74.2890 74.2890
Support 3 (S3) 74.2890 74.2890 74.2890
Support 4 (S4) 74.2890